Person:
Arranz-Herrero, Javier

Profile Picture
First Name
Javier
Last Name
Arranz-Herrero
Institution
ISCIII
Centrre
ISCIII::Centro Nacional de Microbiología (CNM)
CNIC Organization
CNIO Organization
Institute
Identifiers
ORCID

Filters

20232
Reset filters

Settings

Has files: true ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Determinants of poor clinical outcome in patients with influenza pneumonia: A systematic review and meta-analysis
    (Elsevier, 2023-06) Arranz-Herrero, Javier; Presa, Jesús; Rius-Rocabert, Sergio; Utrero-Rico, Alberto; Arranz-Arija, José Ángel; Lalueza, Antonio; Escribese, María M; Ochando, Jordi; Soriano, Vicente; Nistal-Villan, Estanislao; Ministerio de Ciencia e Innovación (España); Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF); CEU San Pablo University; Unión Europea. Fondo Social Europeo (ESF/FSE); Instituto de Salud Carlos III; National Institutes of Health (Estados Unidos)
    Background: The clinical burden of influenza is increasing worldwide. Aging, immunosuppression, and underlying respiratory illness are determinants of poor clinical outcomes, including greater mortality. Bacterial infections seem to be the main reason. Updated information on the role of bacterial infection as the cause of complications would be of value in improving the prognosis of patients with influenza. Methods: A systematic review and meta-analysis were performed by using the PubMed repository using keywords like: Influenza, H1N1, Streptococcus pneumoniae, bacterial coinfection, secondary coinfection, bacterial complications in pneumonia, and seasonal influenza. Only articles written in English were included in publications from 2010 to 2020. The analyses were conducted following the preferred reporting items for systematic review and meta-analyses guidelines. The results were independently validated using a TrinetX database cohort of roughly 4 million patients. Results: We included 135 studies that contained data from 48,259 patients hospitalized with influenza of any age. Bacterial infections were diagnosed in 5391 (11.2%). Streptococcus pneumoniae (30.7%) and Staphylococcus aureus (30.4%) were the most frequent microorganisms, followed by Haemophilus influenzae (7.1%) and Pseudomonas aeruginosa (5.9%). The random-effects model of the meta-analysis indicated that bacterial infections posed a 3.4-fold increased risk of death compared with influenza infection alone. Unexpectedly, asthma was protective (odds ratio 0.8). Conclusion: Bacterial infections diagnosed in 11.2% of patients with influenza increase 3.4-fold the mortality risk. S. pneumoniae, S. aureus, H. influenzae, and P. aeruginosa account for nearly 75% of the cases. Earlier diagnosis and use of antibiotics should improve outcomes in this population.
  • Thumbnail Image
    Publication
    The Many Ways to Deal with STING
    (Multidisciplinary Digital Publishing Institute (MDPI), 2023-05-20) Coderch, Claire; Arranz-Herrero, Javier; Nistal-Villan, Estanislao; de Pascual-Teresa, Beatriz; Rius-Rocabert, Sergio; Ministerio de Ciencia e Innovación (España); Agencia Estatal de Investigación (España); Instituto de Salud Carlos III; Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
    The stimulator of interferon genes (STING) is an adaptor protein involved in the activation of IFN-β and many other genes associated with the immune response activation in vertebrates. STING induction has gained attention from different angles such as the potential to trigger an early immune response against different signs of infection and cell damage, or to be used as an adjuvant in cancer immune treatments. Pharmacological control of aberrant STING activation can be used to mitigate the pathology of some autoimmune diseases. The STING structure has a well-defined ligand binding site that can harbor natural ligands such as specific purine cyclic di-nucleotides (CDN). In addition to a canonical stimulation by CDNs, other non-canonical stimuli have also been described, whose exact mechanism has not been well defined. Understanding the molecular insights underlying the activation of STING is important to realize the different angles that need to be considered when designing new STING-binding molecules as therapeutic drugs since STING acts as a versatile platform for immune modulators. This review analyzes the different determinants of STING regulation from the structural, molecular, and cell biology points of view.